GLOW

GLOW is a seller-defined name. Ingredient list and proportions differ between formulations, and exact amounts are formulation-specific rather than a property of the name.

• GHK-Cu — read the evidence profile
• BPC-157 — read the evidence profile
• TB-500 — read the evidence profile

  TB-500 material may be a thymosin beta-4 fragment rather than the full peptide; the naming is not standardised.

Blends are mixtures sold under a nickname. The name is chosen by whoever is selling it, so two vials with the same name can contain different ingredients in different amounts. Any evidence level shown here describes the combined marketed mixture, which is almost always untested as a mixture.

• No blend-specific controlled human evidence identified in the curated record.

GHK-Cu's better-quality human evidence sits in topical cosmetic use, and thymosin beta-4 evidence sits in preclinical work. Neither transfers to an injected mixture: topical cosmetic results are not evidence for injection, and preclinical results are not human evidence at all.

Because the name is defined by whoever markets it, the same three letters can describe materially different products.

• Whether injected GHK-Cu produces anything like the effects reported for topical GHK-Cu — this has not been established.
• Copper content and handling in an injectable preparation.
• Ingredient proportions, which are formulation-specific.
• Purity, sterility and label accuracy of the finished mixture.

GHK-Cu is regulated as a cosmetic ingredient in topical products; that status does not extend to an injectable mixture. No regulator has approved GLOW or any equivalent injectable blend.

• No controlled human safety data for the injected mixture.
• Local reactions and systemic effects of injected copper peptide complexes are not characterised in controlled human research.
• Unregulated injectable supply adds contamination and mislabelling risk on top of the unknown pharmacology.